1. <cite id="5wyk8"><noscript id="5wyk8"></noscript></cite>
      <tt id="5wyk8"><noscript id="5wyk8"></noscript></tt>
      <tt id="5wyk8"><noscript id="5wyk8"></noscript></tt>

        <rt id="5wyk8"><meter id="5wyk8"></meter></rt>
          <source id="5wyk8"><menuitem id="5wyk8"></menuitem></source>
          <rt id="5wyk8"><optgroup id="5wyk8"></optgroup></rt>
        1. <ruby id="5wyk8"></ruby>

          Advancing Global Health

          Gilead recognizes that the development of innovative medicines for life-threatening diseases is only one aspect of improving public health. We also invest in programs that promote prevention, strengthen healthcare infrastructure, and provide education and social and financial support to the most vulnerable communities around the world.

          By enabling access to medicines, challenging assumptions, fighting stigma and collaborating with partners worldwide, we work not simply to treat some of the world’s most challenging public health threats – but to eliminate them.

          Expanding Treatment Access

          Expanding Treatment Access in Low and Middle Income Countries

          Gilead’s dedicated Access team meets with public health officials, doctors and patients around the world to understand barriers and opportunities in HIV, viral hepatitis and visceral leishmaniasis (VL) treatment access.

          Read more

          Gilead Sciences and WHO tackle VL in South East Asia

          Visceral leishmaniasis (VL) is a parasitic disease with an estimated 50,000 to 90,000 new cases worldwide each year, out of which only an estimated 25 to 45% are reported. VL is almost always fatal if untreated. We are collaborating with the World Health Organization (WHO) to provide AmBisome® free of charge to all patients diagnosed with the disease.

          Learn more

          Image of AmBisome vial

          Infographic: Of every 100 people infected with Hepatitis C, 60-70 people will develop chronic liver disease

          Helping eliminate chronic hepatitis C worldwide

          WHO is working to eliminate viral hepatitis worldwide by 2030. Through awareness, screening and care, we’re helping governments, patients and payers in efforts to eliminate the chronic hepatitis C virus (HCV) and end the disease.

          Learn more

          Partnerships aim to address the threat of Ebola

          As part of our determination to contain and eliminate public health threats around the world, we’re partnering with public health agencies, NGOs, universities and defense agencies on clinical trials of remdesivir as a treatment for Ebola and other emerging viruses.

          Learn more

          Ebola virus under microscope

          Group of young woman involved in PEPFAR

          Keeping girls and young women HIV-free in sub-Saharan countries

          Gilead partners with the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) to help reduce HIV infections in adolescent girls and young women in 10 sub-Saharan African countries. The DREAMS program has helped cut new diagnoses by up to 40 percent.

          Learn more

          Italy’s first HIV/HCV support center for LGBT population

          BLQ Checkpoint in Bologna, Italy – supported by Gilead – is Italy’s first and only community HIV and HCV testing center. It also offers support, counseling, education and a comfortable environment for members of the LGBT community.

          Learn more

          Two men shaking hands